Suicide gene therapy for graft-versus-host disease

Immunotherapy

Volumn 2, Issue 4, 2010, Pages 521-537

  Georgoudaki, Anna Maria ^a   Sutlu, Tolga ^a   Alici, Evren ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Huddinge   (Sweden)

Author keywords

allogeneic stem cell transplantation; cytosine deaminase; donor lymphocyte infusion; graft versus host disease; graft versus infection; graft versus leukemia; herpes simplex virus thymidine kinase; selection marker; suicide gene therapy

Indexed keywords

CLINICAL ASSESSMENT; CLINICAL TRIAL; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; REVIEW; SUICIDE GENE; SUICIDE GENE THERAPY; TARGET CELL;

GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; T-LYMPHOCYTES;

EID: 77954966694     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.19     Document Type: Review

References (167)

1. Horowitz MM, Gale RP, Sondel PM et al.: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75(3), 555-562 (1990).
2. Tomblyn M, Lazarus HM: Donor lymphocyte infusions: the long and winding road: how should it be traveled? Bone Marrow Transplant. 42(9), 569-579 (2008).
3. Kolb HJ, Schattenberg A, Goldman JM et al.: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86(5), 2041-2050 (1995).
4. Cullis JO, Jiang YZ, Schwarer AP, Hughes TP, Barrett AJ, Goldman JM: Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 79(5), 1379-1381 (1992).
5. Drobyski WR, Keever CA, Roth MS et al.: Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 82(8), 2310-2318 (1993).
6. van Rhee F, Lin F, Cullis JO et al.: Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 83(11), 3377-3383 (1994).
7. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH: Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N. Engl. J. Med. 330(2), 100-106 (1994).
8. Mackinnon S, Papadopoulos EB, Carabasi MH et al.: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86(4), 1261-1268 (1995).
9. Bar BM, Schattenberg A, Mensink EJ et al.: Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J. Clin. Oncol. 11(3), 513-519 (1993). (Pubitemid 23071050)
10. Collins RH, Jr., Shpilberg O, Drobyski WR et al.: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 15(2), 433-444 (1997).
11. Sehn LH, Alyea EP, Weller E et al.: Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: Impact of donor lymphocyte infusion. J. Clin. Oncol. 17(2), 561-568 (1999).
12. Helg C, Starobinski M, Jeannet M, Chapuis B: Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation. Leuk. Lymphoma 29(3-4), 301-313 (1998)
13. Aversa F, Tabilio A, Velardi A et al.: Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N. Engl. J. Med. 339(17), 1186-1193 (1998).
14. Nakamura K, Inaba M, Sugiura K et al.: Enhancement of allogeneic hematopoietic stem cell engraftment and prevention of GVHD by intra-bone marrow bone marrow transplantation plus donor lymphocyte infusion. Stem Cells 22(2), 125-134 (2004).
15. Ferrara JL, Levine JE, Reddy P, Holler E: Graft-versus-host disease. Lancet 373(9674), 1550-1561 (2009).
16. Martin PJ, Schoch G, Fisher L et al.: A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 76(8), 1464-1472 (1990).
17. Vogelsang GB, Lee L, Bensen-Kennedy DM: Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu. Rev. Med. 54, 29-52 (2003).
18. Ferrara JL, Deeg HJ: Graft-versus-host disease. N. Engl. J. Med. 324(10), 667-674 (1991).
19. Sullivan KM, Agura E, Anasetti C et al.: Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin. Hematol. 28(3), 250-259 (1991).
20. Sullivan KM, Mori M, Sanders J et al.: Late complications of allogeneic and autologous marrow transplantation. Bone Marrow Transplant. 10(Suppl. 1), 127-134 (1992).
21. Filipovich AH, Weisdorf D, Pavletic S et al.: National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol. Blood Marrow Transplant. 11(12), 945-956 (2005). (Pubitemid 41754712)
22. Toubai T, Sun Y, Reddy P: GvHD pathophysiology: is acute different from chronic? Best Pract. Res. Clin. Haematol. 21(2), 101-117 (2008).
23. Baurmann H, Nagel S, Binder T, Neubauer A, Siegert W, Huhn D: Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Blood 92(10), 3582-3590 (1998).
24. Spaner D, Sheng-Tanner X, Schuh AC: Aberrant regulation of superantigen responses during T-cell reconstitution and graft-versus-host disease in immunodeficient mice. Blood 100(6), 2216-2224 (2002).
25. Orsini E, Alyea EP, Schlossman R et al.: Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Bone Marrow Transplant. 25(6), 623-632 (2000).
26. Raimondi G, Turner MS, Thomson AW, Morel PA: Naturally occurring regulatory T cells: recent insights in health and disease. Crit. Rev. Immunol. 27(1), 61-95 (2007).
27. Barrett AJ, Rezvani K, Solomon S et al.: New developments in allotransplant immunology. Hematology Am. Soc. Hematol. Educ. Program 350-371 (2003).
28. Cohen SB, Morgan CL, Perez-Cruz I, Perandin F, Martinez B, Madrigal JA: Cord blood serum does not increase lymphocyte responses in comparison to adult serum. Hum. Immunol. 61(2), 111-114 (2000).
29. +CD25+ immunoregulatory T cells for the control of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation. Transplantation 77(1 Suppl.), S32-S34 (2004).
30. Billingham RE: The biology of graft-versus-host reactions. Harvey Lect. 62, 21-78 (1966).
31. Petersdorf EW, Longton GM, Anasetti C et al.: The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 86(4), 1606-1613 (1995).
32. Krensky AM, Weiss A, Crabtree G, Davis MM, Parham P: T-lymphocyte-antigen interactions in transplant rejection. N. Engl. J. Med. 322(8), 510-517 (1990).
33. Loiseau P, Busson M, Balere ML et al.: HLA association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival. Biol. Blood Marrow Transplant. 13(8), 965-974 (2007).
34. Ratanatharathorn V, Nash RA, Przepiorka D et al.: Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92(7), 2303-2314 (1998).
35. Anasetti C, Rybka W, Sullivan KM, Banaji M, Slichter SJ: Graft-v-host disease is associated with autoimmune-like thrombocytopenia. Blood 73(4), 1054-1058 (1989).
36. Flomenberg N, Baxter-Lowe LA, Confer D et al.: Impact of HLA Class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 104(7), 1923-1930 (2004).
37. Goulmy E, Schipper R, Pool J et al.: Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N. Engl. J. Med. 334(5), 281-285 (1996).
38. Falkenburg JH, Goselink HM, van der Harst D et al.: Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J. Exp. Med. 174(1), 27-33 (1991).
39. Cavet J, Middleton PG, Segall M, Noreen H, Davies SM, Dickinson AM: Recipient tumor necrosis factor-α and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood 94(11), 3941-3946 (1999).
40. Lin MT, Storer B, Martin PJ et al.: Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N. Engl. J. Med. 349(23), 2201-2210 (2003).
41. Dickinson AM, Charron D: Non-HLA immunogenetics in hematopoietic stem cell transplantation. Curr. Opin. Immunol. 17(5), 517-525 (2005). (Pubitemid 41207956)
42. Miller JS, Soignier Y, Panoskaltsis-Mortari A et al.: Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105(8), 3051-3057 (2005).
43. Miller JS, Cooley S, Parham P et al.: Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GvHD) following unrelated donor allogeneic hct. Blood 109(11), 5058-5061 (2007).
44. Velardi A, Ruggeri L, Moretta A, Moretta L: NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol. 23(9), 438-444 (2002).
45. Parham P, McQueen KL: Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nat. Rev. Immunol. 3(2), 108-122 (2003).
46. Ferrara JL, Reddy P: Pathophysiology of graft-versus-host disease. Semin. Hematol. 43(1), 3-10 (2006).
47. Holler E: Cytokines, viruses, and graft-versus-host disease. Curr. Opin. Hematol. 9(6), 479-484 (2002).
48. Matzinger P: The danger model: a renewed sense of self. Science 296(5566), 301-305 (2002).
49. Goker H, Haznedaroglu IC, Chao NJ: Acute graft-vs-host disease: pathobiology and management. Exp. Hematol. 29(3), 259-277 (2001).
50. + graft-versus-host-reactive effector cells. J. Immunol. 181(10), 6820-6828 (2008).
51. Laurin D, Hannani D, Pernollet M et al.: Immunomonitoring of graft-versus-host minor histocompatibility antigen correlates with graft-versus-host disease and absence of relapse after graft. Transfusion 50(2), 418-428 (2010).
52. Cohen JL, Boyer O, Thomas-Vaslin V, Klatzmann D: Suicide gene-mediated modulation of graft-versus-host disease. Leuk. Lymphoma 34(5-6), 473-480 (1999).
53. + T cells. Hum. Gene Ther. 15(7), 648-658 (2004).
54. Cohen JL, Boyer O, Salomon B et al.: Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes. Blood 89(12), 4636-4645 (1997).
55. Helene M, Lake-Bullock V, Bryson JS, Jennings CD, Kaplan AM: Inhibition of graft-versus-host disease. Use of a T cell-controlled suicide gene. J. Immunol. 158(11), 5079-5082 (1997).
56. Slavin S, Ackerstein A, Naparstek E, Or R, Weiss L: The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD? Bone Marrow Transplant. 6(3), 155-161 (1990).
57. Tiberghien P, Cahn JY, Brion A et al.: Use of donor T-lymphocytes expressing herpes-simplex thymidine kinase in allogeneic bone marrow transplantation: a Phase I-II study. Hum. Gene Ther. 8(5), 615-624 (1997).
58. Fehse B, Ayuk FA, Kroger N et al.: Evidence for increased risk of secondary graft failure after in vivo depletion of suicide gene-modified T lymphocytes transplanted in conjunction with CD34+-enriched blood stem cells. Blood 104(10), 3408-3409 (2004).
59. Tiberghien P: Use of suicide gene-expressing donor T-cells to control alloreactivity after haematopoietic stem cell transplantation. J. Intern. Med. 249(4), 369-377 (2001).
60. Giralt S, Estey E, Albitar M et al.: Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89(12), 4531-4536 (1997).
61. Scaife MD, Neschadim A, Fowler DH, Medin JA: Novel application of lentiviral vectors towards treatment of graft-versus-host disease. Expert Opin. Biol. Ther. 9(6), 749-761 (2009).
62. Kaneko S, Mastaglio S, Bondanza A et al.: Il-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood 113(5), 1006-1015 (2009).
63. Robinet E, Fehse B, Ebeling S, Sauce D, Ferrand C, Tiberghien P: Improving the ex vivo retroviral-mediated suicide-gene transfer process in T lymphocytes to preserve immune function. Cytotherapy 7(2), 150-157 (2005).
64. Marktel S, Magnani Z, Ciceri F et al.: Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood 101(4), 1290-1298 (2003).
65. Berger C, Blau CA, Clackson T, Riddell SR, Heimfeld S: CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy. Blood 101(2), 476-484 (2003).
66. Sauce D, Tonnelier N, Duperrier A et al.: Influence of Ex vivo expansion and retrovirus-mediated gene transfer on primary T lymphocyte phenotype and functions. J. Hematother. Stem Cell Res. 11(6), 929-940 (2002).
67. Kuhlcke K, Fehse B, Schilz A et al.: Highly efficient retroviral gene transfer based on centrifugation-mediated vector preloading of tissue culture vessels. Mol. Ther. 5(4), 473-478 (2002).
68. Sauce D, Bodinier M, Garin M et al.: Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein- Barr virus potential through both culture-dependent and selection process-dependent mechanisms. Blood 99(4), 1165-1173 (2002).
69. Ferrand C, Robinet E, Contassot E et al.: Retrovirus-mediated gene transfer in primary T lymphocytes: influence of the transduction/selection process and of ex vivo expansion on the T cell receptor b chain hypervariable region repertoire. Hum. Gene Ther. 11(8), 1151-1164 (2000).
70. Pollok KE, Williams DA: Facilitation of retrovirus-mediated gene transfer into hematopoietic stem and progenitor cells and peripheral blood T-lymphocytes utilizing recombinant fibronectin fragments. Curr. Opin. Mol. Ther. 1(5), 595-604 (1999).
71. Ayuk F, Li Z, Kuhlcke K et al.: Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirements. Gene Ther. 6(10), 1788-1792 (1999).
72. Drobyski WR, Majewski D, Ozker K, Hanson G: Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment. J. Immunol. 161(5), 2610-2619 (1998).
73. Fehse B, Schade UM, Li Z et al.: Highly-efficient gene transfer with retroviral vectors into human T lymphocytes on fibronectin. Br. J. Haematol. 102(2), 566-574 (1998). (Pubitemid 28346601)
74. Bunnell BA, Muul LM, Donahue RE, Blaese RM, Morgan RA: High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. Proc. Natl Acad. Sci. USA 92(17), 7739-7743 (1995).
75. Hacein-Bey-Abina S, Garrigue A, Wang GP et al.: Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-x1. J. Clin. Invest. 118(9), 3132-3142 (2008).
76. Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al.: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302(5644), 415-419 (2003).
77. Li CM, Park JH, Simonaro CM et al.: Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes. Genomics 79(2), 218-224 (2002).
78. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F: HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110(4), 521-529 (2002).
79. Montini E, Cesana D, Schmidt M et al.: Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 24(6), 687-696 (2006).
80. Montini E, Cesana D, Schmidt M et al.: The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J. Clin. Invest. 119(4), 964-975 (2009).
81. Dick JE: Stem cell concepts renew cancer research. Blood 112(13), 4793-4807 (2008).
82. Newrzela S, Cornils K, Li Z et al.: Resistance of mature T cells to oncogene transformation. Blood 112(6), 2278-2286 (2008).
83. Baum C, Kustikova O, Modlich U, Li Z, Fehse B: Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum. Gene Ther. 17(3), 253-263 (2006).
84. Bonini C, Bordignon C: Potential and limitations of hsv-tk-transduced donor peripheral blood lymphocytes after allo-BMT. Hematol. Cell Ther 39(5), 273-274 (1997).
85. Garin MI, Garrett E, Tiberghien P et al.: Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood 97(1), 122-129 (2001).
86. Chalmers D, Ferrand C, Apperley JF et al.: Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene. Mol. Ther. 4(2), 146-148 (2001).
87. Tomicic MT, Thust R, Kaina B: Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: critical role of DNA breaks, BCL-2 decline and caspase-9 activation. Oncogene 21(14), 2141-2153 (2002).
88. Adachi M, Sampath J, Lan LB et al.: Expression of MRP4 confers resistance to ganciclovir and compromises bystander cell killing. J. Biol. Chem. 277(41), 38998-39004 (2002).
89. Riddell SR, Elliott M, Lewinsohn DA et al.: T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat. Med. 2(2), 216-223 (1996).
90. Rosenzweig M, Connole M, Glickman R et al.: Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34+ hematopoietic cells. Blood 97(7), 1951-1959 (2001).
91. Verzeletti S, Bonini C, Marktel S et al.: Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Hum. Gene Ther. 9(15), 2243-2251 (1998).
92. Lutzko C, Kruth S, Abrams-Ogg AC et al.: Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine a-l-iduronidase deficiency. Blood 93(6), 1895-1905 (1999).
93. Berger C, Flowers ME, Warren EH, Riddell SR: Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-tk-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107(6), 2294-2302 (2006).
94. Traversari C, Marktel S, Magnani Z et al.: The potential immunogenicity of the tk suicide gene does not prevent full clinical benefit associated with the use of tk-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood 109(11), 4708-4715 (2007).
95. Miller AD, Rosman GJ: Improved retroviral vectors for gene transfer and expression. Biotechniques 7(9), 980-982, 984-986, 989-990 (1989).
96. Licht T, Aksentijevich I, Gottesman MM, Pastan I: Efficient expression of functional human mdr1 gene in murine bone marrow after retroviral transduction of purified hematopoietic stem cells. Blood 86(1), 111-121 (1995).
97. Nolan GP, Fiering S, Nicolas JF, Herzenberg LA: Fluorescence-activated cell analysis and sorting of viable mammalian cells based on b-d-galactosidase activity after transduction of E. coli lacz. Proc. Natl Acad. Sci. USA 85(8), 2603-2607 (1988).
98. Mavilio F, Ferrari G, Rossini S et al.: Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. Blood 83(7), 1988-1997 (1994).
99. Pawliuk R, Kay R, Lansdorp P, Humphries RK: Selection of retrovirally transduced hematopoietic cells using CD24 as a marker of gene transfer. Blood 84(9), 2868-2877 (1994).
100. Planelles V, Haislip A, Withers-Ward ES et al.: A new reporter system for detection of retroviral infection. Gene Ther. 2(6), 369-376 (1995).
101. Fehse B, Richters A, Putimtseva-Scharf K et al.: CD34 splice variant: an attractive marker for selection of gene-modified cells. Mol. Ther. 1(5 Pt 1), 448-456 (2000).
102. Li Z, Dullmann J, Schiedlmeier B et al.: Murine leukemia induced by retroviral gene marking. Science 296(5567), 497 (2002).
103. Bonini C, Grez M, Traversari C et al.: Safety of retroviral gene marking with a truncated NGF receptor. Nat Med 9(4), 367-369 (2003).
104. Li Z, Beutel G, Rhein M et al.: High-affinity neurotrophin receptors and ligands promote leukemogenesis. Blood 113(9), 2028-2037 (2009).
105. Aints A, Belusa R, Andersson RM, Guven H, Dilber MS: Enhanced ouabain resistance gene as a eukaryotic selection marker. Hum. Gene Ther. 13(8), 969-977 (2002).
106. Treschow A, Unger C, Aints A, Felldin U, Aschan J, Dilber MS: Ouaselect, a novel ouabain-resistant human marker gene that allows efficient cell selection within 48 h. Gene Ther. 14(22), 1564-1572 (2007).
107. Portsmouth D, Avaty J, Renner M: Suicide genes for cancer therapy. Mol. Aspects Med. 28, 4-41 (2007).
108. Knox RJ, Friedlos F, Boland MP: The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Cancer Metastasis Rev. 12, 195-212 (1993).
109. Palmer DH, Mautner V, Mirza D et al.: Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J. Clin. Oncol. 22, 1546-1552 (2004).
110. Wei MX, Tamiya T, Chase M et al.: Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum. Gene Ther. 5, 969-978 (1994).
111. Lohr M, Bago ZT, Bergmeister H et al.: Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced-stage pancreatic carcinoma: a Phase I/II study. J. Mol. Med. 77, 393-398 (1999).
112. Salmons B, Lohr M, Gunzburg WH: Treatment of inoperable pancreatic carcinoma using a cell-based local chemotherapy: results of a Phase I/II clinical trial. J. Gastroenterol. 38(Suppl. 15), 78-84 (2003).
113. Straathof KC, Pule MA, Yotnda P et al.: An inducible caspase 9 safety switch for T-cell therapy. Blood 105, 4247-4254 (2005).
114. Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK: Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol. Blood Marrow Transplant. 13, 913-924 (2007).
115. Introna M, Barbui AM, Bambacioni F et al.: Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum. Gene Ther. 11, 611-620 (2000).
116. Till BG, Jensen MC, Wang J et al.: Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20- specific T cells. Blood 112, 2261-2271 (2008).
117. Sato T, Neschadim A, Konrad M, Fowler DH, Lavie A, Medin JA: Engineered human TMPK/AZT as a novel enzyme/ prodrug axis for suicide gene therapy. Mol. Ther. 15, 962-970 (2007).
118. Thomis DC, Marktel S, Bonini C et al.: A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 97, 1249-1257 (2001).
119. Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 46, 5276-5281 (1986).
120. Bordignon C, Bonini C, Verzeletti S et al.: Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum. Gene Ther. 6, 813-819 (1995).
121. Bonini C, Bordignon C: Potential and limitations of HSV-tk-transduced donor peripheral blood lymphocytes after allo-BMT. Hematol. Cell Ther 39, 273-274 (1997).
122. Tiberghien P: Use of suicide gene-expressing donor T-cells to control alloreactivity after haematopoietic stem cell transplantation. J. Intern. Med. 249, 369-377 (2001).
123. Burt RK, Drobyski WR, Seregina T et al.: Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions. Exp. Hematol. 31, 903-910 (2003).
124. Fehse B, Ayuk FA, Kroger N et al.: Evidence for increased risk of secondary graft failure after in vivo depletion of suicide gene-modified T lymphocytes transplanted in conjunction with CD34+-enriched blood stem cells. Blood 104, 3408-3409 (2004).
125. Ciceri F, Bonini C, Marktel S et al.: Antitumor effects of HSV-tk-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 109, 4698-4707 (2007).
126. Ciceri F, Bonini C, Stanghellini MT et al.: Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised Phase I-II study. Lancet Oncol. 10, 489-500 (2009).
127. Mullen CA, Kilstrup M, Blaese RM: Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl Acad. Sci. USA 89, 33-37 (1992).
128. Crystal RG, Hirschowitz E, Lieberman M et al.: Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum. Gene Ther. 8, 985-1001 (1997).
129. Cunningham C, Nemunaitis J: A Phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001. Hum. Gene Ther. 12, 1594-1596 (2001).
130. Freytag SO, Khil M, Stricker H et al.: Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 62, 4968-4976 (2002).
131. Nemunaitis, J, Cunningham C, Senzer N et al.: Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther. 10, 737-744 (2003).
132. Mulligan RC, Berg P: Expression of a bacterial gene in mammalian cells. Science 209, 1422-1427 (1980).
133. Sorscher EJ, Peng S, Bebok Z, Allan PW, Bennett LL Jr, Parker WB: Tumor cell bystander killing in colonic carcinoma utilizing the E. coli deoD gene to generate toxic purines. Gene Ther. 1, 233-238 (1994).
134. Averett, DR, Koszalka GW, Fyfe JA, Roberts GB, Purifoy DJ, Krenitsky TA: 6-methoxypurine arabinoside as a selective and potent inhibitor of varicella-zoster virus. Antimicrob. Agents Chemother. 35, 851-857 (1991).
135. Cortes ML, de Felipe P, Martin V, Hughes MA, Izquierdo M: Successful use of a plant gene in the treatment of cancer in vivo. Gene Ther. 5, 1499-1507 (1998).
136. Rodrigues, ML, Carter P, Wirth C, Mullins S, Lee A, Blackburn BK: Synthesis and b-lactamase-mediated activation of a cephalosporin-taxol prodrug. Chem. Biol. 2, 223-227 (1995).
137. Barnes DW, Corp MJ, Loutit JF, Neal FE: Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. Br. Med. J. 2(4993), 626-627 (1956).
138. Barnes DW, Ilbery PL, Loutit JF: Avoidance of secondary disease in radiation chimaeras. Nature 181(4607), 488 (1958)
139. Boak JL, Fox M, Wilson RE: Activity of lymphoid tissues from antilymphocyte-serum-treated mice. Lancet 1(7493), 750-752 (1967).
140. Bortin MM, Rimm AA, Saltzstein EC, Rodey GE: Graft versus leukemia. 3. Apparent independent anthost and antileukemia activity of transplanted immunocompetent cells. Transplantation 16(3), 182-188 (1973).
141. Bortin MM, Truitt RL, Rimm AA, Bach FH: Graft-versus-leukaemia reactivity induced by alloimmunisation without augmentation of graft-versus-host reactivity. Nature 281(5731), 490-491 (1979).
142. Brent L, Courtenay T, Gowland G: Immunological reactivity of lymphoid cells after treatment with anti-lymphocytic serum. Nature 215(5109), 1461-1464 (1967).
143. Chalandon Y, Roosnek E, Mermillod B, Waelchli L, Helg C, Chapuis B: Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective Phase II study. Biol. Blood Marrow Transplant. 12(1), 102-110 (2006).
144. Couriel D, Saliba R, Hicks K et al.: Tumor necrosis factor-α blockade for the treatment of acute gvhd. Blood 104(3), 649-654 (2004).
145. den Haan JM, Sherman NE, Blokland E et al.: Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 268(5216), 1476-1480 (1995).
146. Guinan EC, Boussiotis VA, Neuberg D et al.: Transplantation of anergic histoincompatible bone marrow allografts. N. Engl. J. Med. 340(22), 1704-1714 (1999).
147. Jacobsohn DA, Hallick J, Anders V, McMillan S, Morris L, Vogelsang GB: Infliximab for steroid-refractory acute GvHD: a case series. Am. J. Hematol. 74(2), 119-124 (2003).
148. Korngold R, Sprent J: Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J. Exp. Med. 148(6), 1687-1698 (1978).
149. Le Blanc K, Rasmusson I, Sundberg B et al.: Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363(9419), 1439-1441 (2004).
150. Levine JE, Paczesny S, Mineishi S et al.: Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 111(4), 2470-2475 (2008).
151. Martin PJ, Hansen JA, Torok-Storb B et al.: Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant. 3(5), 445-456 (1988).
152. Mielke S, Nunes R, Rezvani K et al.: A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood 111(8), 4392-4402 (2008)
153. Prentice HG, Blacklock HA, Janossy G et al.: Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients. Lancet 1(8375), 472-476 (1984).
154. Reisner Y, Kapoor N, Kirkpatrick D et al.: Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet 2(8242), 327-331 (1981).
155. Ruggeri L, Capanni M, Urbani E et al.: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295(5562), 2097-2100 (2002).
156. Sato K, Yamashita N, Baba M, Matsuyama T: Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood 101(9), 3581-3589 (2003).
157. Storb R, Deeg HJ, Whitehead J et al.: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N. Engl. J. Med. 314(12), 729-735 (1986). (Pubitemid 16124386)
158. Storb R, Epstein RB, Graham TC, Thomas ED: Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 9(3), 240-246 (1970).
159. +CD25+ immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99(10), 3493-3499 (2002).
160. Thomas ED, Buckner CD, Rudolph RH et al.: Allogeneic marrow grafting for hematologic malignancy using HL-A matched donor-recipient sibling pairs. Blood 38(3), 267-287 (1971).
161. Thomas ED, Collins JA, Herman EC Jr, Ferrebee JW: Marrow transplants in lethally irradiated dogs given methotrexate. Blood 19, 217-228 (1962).
162. Tiberghien P, Cahn JY, Contassot E, Ferrand C, Reynolds CW, Herve P: Gene transfer applied to the modulation of alloreactivity. Hematol. Cell Ther. 38(2), 221-224 (1996).
163. Uphoff DE: Genetic factors influencing irradiation protection by bone marrow. I. The F1 hybrid effect. J. Natl Cancer Inst. 19(1), 123-130 (1957).
164. Uphoff DE: Alteration of homograft reaction by A-methopterin in lethally irradiated mice treated with homologous marrow. Proc. Soc. Exp. Biol. Med. 99(3), 651-653 (1958).
165. Urbano-Ispizua A, Rozman C, Martinez C et al.: Rapid engraftment without significant graft-versus-host disease after allogeneic transplantation of CD34+ selected cells from peripheral blood. Blood 89(11), 3967-3973 (1997).
166. Weiden PL, Flournoy N, Thomas ED et al.: Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 300(19), 1068-1073 (1979).
167. + T cells reciprocally regulate acute graft versus host disease. J. Exp. Med. 189(7), 1073-1081 (1999).